---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-25-000008"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T04:49:08.568737+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3

## Summary
- Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.
- Phase 2b PROGRESS study of pilavapadin met objectives; 10mg dose showed meaningful pain reduction vs placebo; Phase 3 targeting 2025.
- Cash and investments $238.0M at Dec 31, 2024, up from $170.0M year-end 2023; full-year net loss $200.4M.
- Company ceased active INPEFA promotion and discontinued Zynquista launch prep after FDA CRL; leaner R&D-focused organization.
- LX9851 IND on track for 2025; sotagliflozin Phase 3 SONATA HCM trial enrolling with 500-patient target.

## SEC filing metadata
- accession: 0001062822-25-000008
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/0001062822-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/lxrx-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-25-000008
- JSON: https://secwatch.observer/filing/0001062822-25-000008.json
- Plain text: https://secwatch.observer/filing/0001062822-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.